Rudolph Anja, Shi Hong, Försti Asta, Hoffmeister Michael, Sainz Juan, Jansen Lina, Hemminki Kari, Brenner Hermann, Chang-Claude Jenny
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
BMC Cancer. 2014 Nov 7;14:817. doi: 10.1186/1471-2407-14-817.
Evidence has accumulated which suggests that sex steroids influence colorectal cancer development and progression. We therefore assessed the association of repeat polymorphisms in the estrogen receptor β gene (ESR2) and the androgen receptor gene (AR) with colorectal cancer risk and prognosis.
The ESR2 CA and AR CAG repeat polymorphisms were genotyped in 1798 cases (746 female, 1052 male) and 1810 controls (732 female, 1078 male), matched for sex, age and county of residence. Colorectal cancer risk associations overall and specific for gender were evaluated using multivariate logistic regression models adjusted for sex, county of residence and age. Associations with overall and disease-specific survival were evaluated using Cox proportional hazard models adjusted for established prognostic factors (diagnosis of other cancer after colorectal cancer diagnosis, detection by screening, treatment with adjuvant chemotherapy, tumour extent, nodal status, distant metastasis, body mass index, age at diagnosis and year of diagnosis) and stratified for grade of differentiation. Heterogeneity in gender specific associations was assessed by comparing models with and without a multiplicative interaction term by means of a likelihood ratio test.
The average number of ESR2 CA repeats was associated with a small 5% increase in colorectal cancer risk (OR = 1.05, 95% CI 1.01-1.10) without significant heterogeneity according to gender or tumoural ESR2 expression. We found no indication for an association between the AR CAG repeat polymorphisms and risk of colorectal cancer. The ESR2 CA and AR CAG repeat polymorphisms were not associated with overall survival or disease specific survival after colorectal cancer diagnosis.
Higher numbers of ESR2 CA repeats are potentially associated with a small increase in colorectal cancer risk. Our study does not support an association between colorectal cancer prognosis and the investigated repeat polymorphisms.
已有证据表明,性类固醇会影响结直肠癌的发生和发展。因此,我们评估了雌激素受体β基因(ESR2)和雄激素受体基因(AR)中的重复多态性与结直肠癌风险及预后的关联。
对1798例患者(746例女性,1052例男性)和1810例对照(732例女性,1078例男性)的ESR2 CA和AR CAG重复多态性进行基因分型,这些对照在性别、年龄和居住县方面与病例相匹配。使用经性别、居住县和年龄调整的多变量逻辑回归模型评估总体以及特定性别的结直肠癌风险关联。使用经既定预后因素(结直肠癌诊断后其他癌症的诊断、筛查检测、辅助化疗治疗、肿瘤范围、淋巴结状态、远处转移、体重指数、诊断年龄和诊断年份)调整并按分化程度分层的Cox比例风险模型评估与总体生存和疾病特异性生存的关联。通过似然比检验比较有和没有乘性交互项的模型,评估性别特异性关联中的异质性。
ESR2 CA重复的平均数量与结直肠癌风险小幅增加5%相关(OR = 1.05,95%CI 1.01 - 1.10),根据性别或肿瘤ESR2表达无显著异质性。我们未发现AR CAG重复多态性与结直肠癌风险之间存在关联的迹象。ESR2 CA和AR CAG重复多态性与结直肠癌诊断后的总体生存或疾病特异性生存无关。
ESR2 CA重复数量较多可能与结直肠癌风险小幅增加相关。我们的研究不支持结直肠癌预后与所研究的重复多态性之间存在关联。